Why Replimune is Gambing on a Third FDA Review After the Ultimate Bureaucratic Reset

Biotech regulatory battles are usually fought in quiet meeting rooms, wrapped in sterile language and dense clinical spreadsheets. But what happened between Replimune and the Food and Drug Administration over the last year was a full-blown public street fight. After getting smacked down twice with regulatory rejections, Replimune is heading back to the table. The company announced it will resubmit its biologics license application for vusolimogene oderparepvec, its engineered herpes simplex virus therapy known simply as RP1, for advanced melanoma.

If you think this is just standard corporate persistence, think again. This isn't the same FDA that slammed the door on Replimune just weeks ago. A sweeping leadership exodus at the top of the federal agency has completely flipped the script, turning what looked like a dead-end clinical program into a high-stakes test case for U.S. biotech innovation.

Traders certainly caught the scent of blood. Wall Street sent Replimune stock skyrocketing as much as 82% the morning the news broke. But beneath the market euphoria lies a crucial question: Did Replimune actually fix its science, or did it just outlast its regulators?

The Drama Behind the Rejections

To understand why this sudden about-face matters, you have to look at the wreckage of the first two attempts. Replimune is developing RP1 to be paired with Bristol Myers Squibb's heavy-hitting immunotherapy Opdivo. The target is advanced melanoma patients who have already progressed on standard anti-PD-1 therapies—essentially, people out of conventional options.

The clinical data from their IGNYTE trial showed real promise. The treatment triggered long, durable responses in a notoriously tough patient population, with a median response duration stretching out to 33.7 months. The problem wasn't the efficacy data itself. It was how Replimune designed the trial.

The FDA threw out the first application in July 2025. The core issue? The IGNYTE study was a single-arm trial. It lacked a control group. Regulators argued that without a direct head-to-head comparison, it was impossible to prove how much of the heavy lifting RP1 was doing versus Opdivo alone.

Replimune pushed back hard, arguing that a randomized control trial for a desperate, late-stage patient population was logistically brutal and ethically questionable. They scrambled for a Type A meeting, tried to stitch together an accelerated approval path, and refiled. In April 2026, the FDA handed them their second Complete Response Letter.

That second rejection brought things to a boiling point. Replimune CEO Sushil Patel didn't hold back, publicly blasting the regulator's review process as inconsistent. He pointed out that the FDA had switched review teams mid-stream and started raising completely different objections than what they had agreed to in earlier feedback sessions. The fallout was immediate and painful. Replimune announced plans to cut staff and drastically scale back its U.S. manufacturing operations. The drug was effectively on life support.

The Clean Slate That Changed Everything

Then the bureaucratic dominoes started to fall. For months, the biotech industry had been quietly fuming over what industry analysts called one of the most restrictive, unpredictable periods in recent FDA history. At the center of that tension was FDA Commissioner Marty Makary and Vinay Prasad, the head of the Center for Biologics Evaluation and Research (CBER).

Under their watch, the agency had taken an uncompromising, strictly traditional stance on trial designs, frequently clashing with companies trying to bring targeted therapies to market via accelerated pathways. Richard Pazdur, the legendary oncology chief who had been tapped to lead the Center for Drug Evaluation and Research (CDER), retired unexpectedly just weeks into his new role. His interim successor, Tracy Beth Høeg, didn't last long either.

By early May 2026, the hardline leadership block was completely gone. Prasad walked out the door. Weeks later, Makary resigned. Right now, the FDA is running on a skeleton crew of interim leaders. Kyle Diamantas, the agency's top food executive, is holding down the fort as acting commissioner. Karim Mikhail is running CBER, and Michael Davis is steering CDER.

Before the ink was even dry on Makary’s resignation, Replimune was back at the negotiating table. The company claims its latest discussions with the new acting leadership were highly collaborative. Instead of the brick wall they hit in April, Replimune found an agency willing to listen. The FDA has now agreed to treat the upcoming resubmission as an "urgent matter" and fast-track the review process, explicitly citing the massive unmet need for these skin cancer patients.

What Actually Changed

This is where you need to look past the corporate press releases. The science behind RP1 hasn't miraculously changed in the last thirty days. The IGNYTE data is exactly the same data that the FDA rejected in April.

What changed is the political and regulatory philosophy at the top of the food chain. BMO Capital Markets analysts captured the industry's collective skepticism perfectly, noting that while the news is an obvious win, it's still unclear what fundamentally altered the FDA’s stance other than the names on the office doors.

There are two ways to look at this shift:

• The Optimistic View: The new acting leadership recognizes that rigid adherence to traditional randomized controlled trials shouldn't stand in the way of treatments showing strong, durable efficacy in dying patients. They are stepping in to correct what the industry viewed as regulatory overreach by the previous administration.
• The Cynical View: Replimune successfully used a political window to bypass a rigorous scientific critique. The previous review teams stood ground on a legitimate scientific principle—that single-arm combination trials are bad science—and the company simply waited for those critics to clear out.

For his part, former Commissioner Makary defended his record before leaving, stating that every single rejection under his watch came from the recommendations of the agency's primary scientific review teams, not executive meddling. But in the real world, the tone set by leadership dictates how those review teams operate. With the old guard gone, the internal pendulum has swung back toward flexibility.

The Stakes for the Biotech Sector

The implications of this resubmission stretch far beyond Replimune's balance sheet. If the FDA approves RP1 based on the single-arm IGNYTE data, it signals a massive green light for the rest of the clinical-stage biotech sector. It proves that the aggressive, standard-shifting era of the past year is officially over.

Companies that have been holding back on filing applications or hesitating to design single-arm trials for rare conditions are watching this case like hawks. An approval here means flexibility is back on the menu at Silver Spring.

But it's a double-edged sword. If the acting leadership team pushes this through too smoothly, they risk facing intense blowback from scientific purists who argue the agency is lowering its standards under industry pressure. It also creates a deeply unstable environment for drug developers who need to know the regulatory rules won't completely flip every time the commissioner's office gets a new occupant.

Preparing for the Market Reaction

For anyone tracking the healthcare sector or holding biotech equities, the Replimune saga provides a clear playbook on how to navigate regulatory regime changes.

First, ignore the initial hype cycles and focus entirely on leadership turnover. When high-level regulators who champion specific, rigid testing standards leave an agency, look immediately at the high-profile casualties of their tenure. The companies that suffered recent rejections under old management are often the first to get a second look from interim directors looking to clear the deck or ease industry tensions.

Second, watch the upcoming advisory committee meetings for RP1 with extreme scrutiny. Even if acting leadership fast-tracks the review, the underlying review staff at the FDA remains largely the same. Watch closely to see if the primary reviewers reiterate their concerns about the missing control group during the public panels, or if the agency pushes for a post-marketing commitment—meaning Replimune gets approval now but must run a randomized trial while the drug is on the market.

The resubmission will hit the FDA's desk in the coming days. If you are positioned in mid-cap biotech, use this timeline to audit other portfolios for similar regulatory logjams. The rules of the game just changed, and Replimune won't be the last company trying to take advantage of the new landscape.